Following NCBIO's Annual Meeting [2], join EY for a live discussion of this year's edition of Beyond Borders. ​Now in its 31st year, Beyond Borders: Staying the Course shows that global biotech companies continued to invest in new treatments despite a pull back from capital markets in the U.S. and the E.U., lower valuations and increased pressure from payers. Still, revenue growth for public biotech companies failed to reach double digits for the first time in two years and net income plummeted by 52%, as the industry continues to be challenged by R&D productivity and the emergence of new business models.

EY has monitored the biotechnology industry for the past 31 years. Hear from Ellen Licking, Senior Analyst, Global Life Sciences Industry, EY, as she reports on financial metrics, deal analysis, investment in the industry, and future global trends. EY is ready to meet you and discuss how they can help you navigate the rapidly changing health care landscape.


This is an additional program feature to the Annual Meeting. Please make sure to register separately for this session. EY must receive all registrations by September 28th. Click here [3] to register for the EY session today!